OKYO Pharma Secures US Patent Covering OK-101's Potential To Treat Symptoms Of Dry Eye Disease
Portfolio Pulse from Benzinga Newsdesk
OKYO Pharma has secured a US patent for OK-101, a novel drug candidate for treating dry eye disease. OK-101 is a lipid conjugated chemerin peptide agonist targeting the ChemR23 receptor on immune cells in the eye, aiming to address inflammatory responses.
August 27, 2024 | 11:01 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
OKYO Pharma has obtained a US patent for OK-101, a drug candidate for dry eye disease, potentially enhancing its market position and future revenue prospects.
The US patent for OK-101 strengthens OKYO Pharma's intellectual property portfolio, potentially increasing its competitive edge and market share in the treatment of dry eye disease. This development is likely to positively impact investor sentiment and the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100